NasdaqGS:AMRXPharmaceuticals
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Green Light For Hospital Epinephrine
In early December 2025, Amneal Pharmaceuticals announced FDA approval for its epinephrine injection USP 1 mg/mL in single- and multi-dose vials, a critical hospital and emergency therapy serving a U.S. market with around US$118 million in annual sales.
Just days earlier, the company also reported encouraging interim Phase 4 ELEVATE-PD data for its CREXONT extended-release Parkinson’s therapy, underscoring progress in higher-value neurology treatments alongside its expanding injectables...